natgillin/translations-raw huggingface dataset:
Relistor was administered every 3.2 days (median dosing interval, with a range of 1-39 days). 
Relistor je davan svaka 3,2 dana (medijan intervala doziranja, s rasponom od 1 do 39 dana).
The dose is given every 48 hours (every two days) as an injection under the skin. 
Doza se daje svakih 48 sati (svaka dva dana) kao injekcija pod kožu.
Due to the safety design of the syringe, a small air bubble may be resistant to removal. 
Zbog sigurnosne konstrukcije štrcaljke, mali mjehurić zraka možda se neće moći ukloniti.
The following packs are available: 
Dostupna su slijedeća pakiranja:
You may use a sharps container (such as a yellow biohazard container). 
Možete upotrijebiti namjensku kutiju za oštre predmete (kao što je žuti spremnik za opasni biološki otpad).
There may be a little bleeding at the injection site. 
Na mjestu injekcije može biti malo krvi.
Talk to your doctor or pharmacist before using Relistor. 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Relistor.
This injection should not be mixed in the same syringe with any other medicine. 
Ova injekcija ne smije se miješati u istoj štrcaljki s drugim lijekom.
If this happens, discard the product and start again using another vial and syringe. 
Ako se to dogodi, bacite proizvod i započnite ponovno s drugom bočicom i štrcaljkom.
This will mean that the safety mechanism has been activated, and the needle will disappear into the syringe. 
To znači da se aktivirao sigurnosni mehanizam i igla će se uvući u štrcaljku.
Has it been 48 hours or longer since your last bowel movement? 
Je li prošlo 48 sati ili više od kada ste zadnji put imali stolicu?
If you push the plunger completely, you will hear a ‘click' sound. 
Ako gurnete klip do kraja, čut ćete “klik”.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti i mogućeg kancerogenog djelovanja.
Dose (mL) = patient weight (kg) x 0.0075 
Doza (ml) = težina bolesnika (kg) x 0,0075
In the event of an overdose, signs and symptoms of orthostatic hypotension should be monitored and reported to a physician. 
U slučaju predoziranja treba pratiti znakove i simptome ortostatske hipotenzije i prijaviti ih liječniku.
This section is divided into the following subsections: 
Ovaj odlomak podijeljen je na sljedeće pododlomke:
Pharmacotherapeutic group: Laxatives, Peripheral opioid receptor antagonists, ATC code: A06AH01 
Farmakoterapijska skupina: Laksativi, Periferni antagonisti opioidnih receptora, ATK oznaka: A06AH01
Constipation not related to opioid use 
Konstipacija koja nije povezana s upotrebom opioida
Always make sure you have the correct dose in the syringe. 
Uvijek se uvjerite da u štrcaljki imate točnu dozu.
Are you mobile enough to reach the toilet, or do you have a caregiver looking after you who can help? 
Jeste li dovoljno pokretni da stignete do zahoda ili imate li stalnog njegovatelja koji Vam može pomoći?
At any time, the patient's assigned dose could be reduced based on tolerability. 
U bilo kojem trenutku bolesnikova doza mogla se smanjiti u skladu s podnošljivošću.
The following side effects are very common and may affect more than 1 in 10 people. 
Slijedeće nuspojave su vrlo česte i mogu se javiti kod više od 1 na 10 osoba.
You may see some fluid or bubbles inside the vial when the syringe is properly filled. 
Vidjet ćete nešto tekućine ili mjehurića u bočici kada se štrcaljka ispravno napuni.
A total of 136, 21, and 82 patients received at least one open-label dose in studies 301, 301EXT, and 302EXT, respectively. 
Ukupno je 136, 21 i 82 bolesnika primilo barem jednu otvorenu dozu u ispitivanjima 301, 301EXT, odnosno 302EXT.
Are you familiar with the technique of self injection or have you discussed this with your doctor (or nurse or pharmacist)? 
Jeste li upoznati s načinima davanja injekcije samom sebi i jeste li o tomu razgovarali s Vašim liječnikom (ili medicinskom sestrom ili ljekarnikom)?
Look at the pre-filled syringe. 
Pogledajte napunjenu štrcaljku.
Patients were required to discontinue all previous laxative therapy. 
Bolesnici su morali prekinuti sa svim ranijim terapijama laksativima.
Studies in animals have shown reproductive toxicity at high doses (see section 5.3). 
Ispitivanja na životinjama pokazala su reproduktivnu toksičnost kod velikih doza (vidjeti dio 5.3).
Therefore, no dose adjustment is recommended based on age. 
Zbog toga se ne preporučuje prilagodba doze u odnosu na dob.
There was no evidence of teratogenicity in rats or rabbits. 
Nije dokazana teratogenost kod štakora ili kunića.
• If you are receiving supportive care for your advanced illness, this medicine will only be used for a limited period of time, which will usually be less than 4 months. 
• Ako primate suportivnu skrb za uznapredovalu bolest, ovaj lijek ćete koristiti samo tijekom ograničenog vremenskog razdoblja, koje će obično biti kraće od 4 mjeseca.
The needle will automatically retract from the skin and be capped. 
Igla će se automatski izvući iz kože i poklopiti.
Other common side effects that may affect up to 1 in 10 people are: 
Druge česte nuspojave, koje se mogu pojaviti u manje od 1 na 10 osoba su:
Other medicines and Relistor 
Drugi lijekovi i Relistor
Make sure not to touch the rubber stopper again. 
Pazite da više ne dodirnete gumeni čep.
Approximately half of the dose is excreted in the urine and somewhat less in faeces. 
Oko polovica doze izlučuje se u urinu, a u manjoj mjeri u stolici.
Once you have drawn the medicine into the syringe, it must be used within 24 hours because Relistor is affected by light and may not work properly if it is left in the syringe for longer than 24 hours. 
Nakon što ste povukli lijek u štrcaljku, morate ga iskoristiti u roku od 24 sata jer na Relistor utječe svjetlost pa je moguće da neće djelovati na odgovarajući način ukoliko stoji u štrcaljki dulje od 24 sata.
What Relistor is and what it is used for 
Što je Relistor i za što se koristi
Due to light sensitivity, the solution for injection should be used within 24 hours. 
Radi osjetljivosti na svjetlost, otopina za injekciju mora se upotrijebiti u roku od 24 sata.
Gender No meaningful gender differences have been observed. 
Nisu opažene značajne razlike s obzirom na spol.
What you need to know before you use Relistor 
Što morate znati prije nego počnete uzimati Relistor
What Relistor looks like and contents of the pack 
Kako Relistor izgleda i sadržaj pakiranja
There may be local laws about how you should throw away used needles and syringes. 
Moguće je da postoje lokalni zakoni o zbrinjavanju korištenih igli i štrcaljki.
In these studies, the median age was 68 years (range 21-100); 51 % were females. 
U ovim ispitivanjima medijan dobi bio je 68 godina (raspon 21 - 100); 51% bolesnika bile su žene.
Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal and/or reduced analgesia. 
Bolesnici koji imaju oštećenje krvno-moždane barijere mogu biti pod povećanim rizikom ustezanja od opioida i/ili smanjene analgezije.
Methylnaltrexone bromide is minimally bound to human plasma proteins (11.0 % to 15.3 %) as determined by equilibrium dialysis. 
Metilnaltreksonbromid se minimalno veže uz proteine ljudske plazme (11,0% do 15,3%), što je određeno metodom ekvilibrijske dijalize.
Methylnaltrexone bromide should not be used during pregnancy unless clearly necessary. 
Metilnaltreksonbromid se ne smije koristiti tijekom trudnoće, osim ako to nije nužno potrebno.
Do you have a contact number for your community nurse or the health centre? 
Imate li telefonski broj Vaše patronažne medicinske sestre ili zdravstvenog centra?
If you receive only the vial, you will need to obtain alcohol swabs and an injection syringe. 
Ako dobijete samo bočicu, morat ćete nabaviti alkoholom natopljene jastučiće i injekcijsku štrcaljku.
After withdrawal in the injection syringe: 
Nakon uvlačenja u štrcaljku za injekciju:
If you have suffered from constipation before you had to take opioids (for pain), please talk to your doctor. 
Ako ste imali zatvor i prije nego što ste počeli uzimati opioide (za ublažavanje bolova) molimo obratite se liječniku.
You may have a bowel movement within a few minutes to a few hours of the injection; therefore, it is recommended to have a toilet facility or bedpan near you. 
Pražnjenje crijeva može nastupiti kroz nekoliko minuta do nekoliko sati nakon injekcije; stoga se preporučuje biti u blizini zahoda ili imati pri ruci noćnu posudu.
There was no evidence of a differential effect of gender on safety or efficacy. 
Nije bilo dokaza koji bi upućivali na to da spol ima učinke na sigurnost ili djelotvornost.
The pre-filled syringe should NEVER be reused. 
Napunjena štrcaljka ne smije se NIKADA ponovno upotrijebiti.
The steady-state volume of distribution (Vss) is approximately 1.1 L/kg. 
Volumen distribucije u stanju dinamičke ravnoteže (Vss) iznosi oko 1,1 l/kg.
Hold the syringe at eye level so that you can see the dosing marks and make sure the tip of the needle is in the fluid all of the time. 
Držite štrcaljku u razini oka, tako da možete vidjeti oznake za dozu i pazite da se vrh igle cijelo vrijeme nalazi u tekućini.
The terminal disposition half-life (t1/2) is approximately 8 hours. 
Terminalno poluvrijeme uklanjanja (t1/2) iznosi oko 8 sati.
Not known: Gastrointestinal perforation (see section 4.4) 
Nepoznato: gastrointestinalna perforacija (vidjeti dio 4.4)
The 8 mg pre-filled syringe will only be used to treat these patients if the dose needs to be decreased because of another medical problem. 
Napunjena štrcaljka od 8 mg će se koristiti za liječenje ovih bolesnika isključivo ako je potrebno smanjiti dozu zbog nekog drugog zdravstvenog problema.
You may receive either a pack containing an inner carton with everything needed for the injection, or a single vial only. 
Možete dobiti pakiranje koje sadrži unutarnju kutiju sa svim potrebnim za injekciju ili pakiranje u kojem se nalazi samo jedna bočica.
(≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). 
(≥ 1/1000 do < 1/100); rijetko (≥ 1/10 000 do < 1/1000); vrlo rijetko (<1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Push the full length of the needle into the skin at a slight angle (45 degrees) with a quick, short motion. 
Gurnite iglu do kraja u kožu pod malim kutom (45 stupnjeva) brzim, kratkim pokretom.
Your doctor will tell you whether you should stop or continue taking your usual laxatives when you start using this medicine. 
Vaš liječnik će Vam reći trebate li prekinuti ili nastaviti s uzimanjem uobičajenih laksativa kada počnete koristiti ovaj lijek.
Pack sizes of 1 vial, 
Veličine pakiranja su 1 bočica,
Data from clinical trials suggest treatment with methylnaltrexone bromide can result in the rapid onset (within 30 to 60 minutes on average) of a bowel movement. 
Podaci iz kliničkih studija upućuju na to da liječenje metilnaltreksonbromidom može dovesti do brzog pražnjenja crijeva (prosječno unutar 30 do 60 minuta).
This should be taken into account when prescribing methylnaltrexone bromide for such patients. 
Ovo treba uzeti u obzir prilikom propisivanja metilnaltreksonbromida takvim bolesnicima.
In vitro metabolism studies suggest that methylnaltrexone bromide does not inhibit the activity of CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 or CYP3A4, while it is a weak inhibitor of the metabolism of a model CYP2D6 substrate. 
In vitro ispitivanja metabolizma pokazuju da metilnaltreksonbromid ne inhibira aktivnost CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 ili CYP3A4, dok je istovremeno slabi inhibitor metabolizma modela CYP2D6 supstrata.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. 
Nositelj odobrenja će periodička izvješća o neškodljivosti za ovaj lijek podnositi u skladu s referentnim popisom datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive
Methylnaltrexone sulphate is an inactive metabolite and present in plasma at a level of approximately 25 % of drug related materials. 
Metilnaltrekson sulfat je inaktivni metabolit i prisutan je u plazmi na razini od oko 25 % tvari povezanih s lijekom.
If it is not, do not use the solution. 
Ako to nije slučaj, nemojte upotrijebiti otopinu.
Patients had a history of chronic non-cancer pain and were taking opioids with stable doses of at least 50 mg of oral morphine equivalents per day. 
Bolesnici su u anamnezi imali kroničnu nemalignu bol i uzimali su opioide u stabilnim dozama ekvivalentnim najmanje 50 mg oralnog morfina dnevno.
It is recommended to move to a different site each time an injection is given. 
Preporučuje se svaki put dati injekciju na drugom mjestu.
The safety and efficacy of methylnaltrexone bromide in children less than 18 years has not been established. 
Sigurnost i djelotvornost metilnaltreksonbromida u djece u dobi do 18 godina nije ustanovljena.
During the first week (days 1, 3, 5, 7), patients received either methylnaltrexone bromide 0.15 mg/kg or placebo. 
Tijekom prvog tjedna (dani 1, 3, 5, 7) bolesnici su primili ili metilnaltreksonbromid od 0,15 mg/kg ili placebo.
However, this resulted in a small reduction in total clearance (from 107 L/h to 95 L/h). 
To je međutim dovelo do manjeg pada ukupnog klirensa (sa 107 l/h na 95 l/h).
The use of methylnaltrexone bromide for treating opioid-induced constipation beyond 48 weeks has not been evaluated in clinical trials. 
Primjena metilnaltreksonbromida za liječenje konstipacije uzrokovane opioidima dulje od 48 tjedana nije ispitivana u kliničkim ispitivanjima.
In this study, the median patient age was 49 years (range 23-83); 60% were females. 
U ovom ispitivanju medijan dobi bolesnika je iznosio 49 godina (raspon 23 - 83); 60% bolesnika bile su žene.
This may have an effect on your ability to drive and use machines. 
To može utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
Use the other hand to gently pinch the cleaned area of skin and hold it firmly. 
Drugom rukom nježno uzmite nabor kože u očišćenom području i čvrsto ga uhvatite.
Do not use Relistor - if you are allergic to methylnaltrexone bromide or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Relistor - Ako ste alergični na metilnaltreksonbromid ili neki drugi sastojak ovog lijeka (naveden u dijelu
The mechanism of this effect is unknown; however, the human cardiac potassium ion channel (hERG) appears not to be involved. 
Mehanizam navedenog učinka nije poznat; međutim, čini se da ne uključuje kalijev ionski kanal kod ljudi (hERG).
Remove the protective plastic cap from the vial. 
Skinite plastičnu zaštitnu kapicu s bočice.
For storage conditions of the medicinal product in the syringe, see section 6.3. 
Uvjete čuvanja lijeka u štrcaljki, vidjeti u dijelu 6.3.
Do not attempt to administer an injection until you are sure that you understand how to prepare and give an injection. 
Nemojte pokušavati dati injekciju dok niste sigurni da razumijete kako pripremiti i dati injekciju.
Patients may receive two consecutive doses 24 hours apart, only when there has been no response (bowel movement) to the dose on the preceding day. 
Bolesnici mogu primiti dvije uzastopne doze u razmaku od 24 sata, samo u slučajevima kada nije bilo odgovora (stolice) na dozu od prethodnog dana.
This allows methylnaltrexone bromide to function as a peripherally acting mu-opioid antagonist in tissues such as the gastrointestinal tract, without impacting opioid-mediated analgesic effects on the central nervous system. 
To omogućuje metilnaltreksonbromidu da djeluje kao periferni antagonist mu-opioidnih receptora u tkivima poput gastrointestinalnog trakta, a da ne utječe na analgetički učinak posredovan opioidima na središnji živčani sustav.
Release your thumb from the plunger to allow the protective sleeve to cover the needle. 
Podignite palac s klipa da omogućite da zaštitni rukavac poklopi iglu.
Select a flat, clean, well-lit working surface where you can lay out the contents of your Relistor carton. 
Odaberite ravnu, čistu, dobro osvijetljenu površinu na koju ćete složiti sadržaj pakiranja
In both studies, there was no evidence to suggest differential effects of age or gender on safety or efficacy. 
U oba ispitivanja nije bilo dokaza koji bi upućivali na to da dob ili spol imaju učinke na djelotvornost ili sigurnost lijeka.
Pack containing 4, 7, 8 or 10 pre-filled syringes with a needle shield. 
Pakiranje koje sadrži 4, 7, 8 ili 10 napunjenih štrcaljki sa štitnikom za iglu.
Relistor is indicated for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. 
Relistor je indiciran za liječenje konstipacije uzrokovane opioidima kada odgovor na terapiju laksativima nije dovoljan u odraslih bolesnika, u dobi od 18 godina i starijih.
It is not recommended to inject into areas where the skin is tender, bruised, red, or hard. 
Ne preporučuje se davanje injekcije na mjestima gdje je koža osjetljiva, natučena, crvena ili tvrda.
Data from 133 (62 methylnaltrexone bromide, 71 placebo) patients were analysed. 
Analizirani su podaci 133 bolesnika (62 metilnaltreksonbromid, 71 placebo).
• Risk Management Plan 
LIJEKA • Plan upravljanja rizikom (RMP)
In the second week, a patient's assigned dose could be increased to 0.30 mg/kg if the patient had 2 or fewer rescue-free laxations up to day 8. 
Tijekom drugog tjedna doza koju su bolesnici primali mogla se povisiti na 0,30 mg/kg ako je bolesnik imao 2 ili manje laksacija bez primjene dodatnog laksativa do 8. dana.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN 
POSEBNO UPOZORENJE O ČUVANJU LIJEKA IZVAN DOHVATA I POGLEDA DJECE
In both studies, patients had advanced terminal illness and limited life expectancy, with the majority having a primary diagnosis of incurable cancer; other primary diagnoses included end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS, or other advanced illnesses. 
U oba ispitivanja bolesnici su imali uznapredovalu terminalnu bolest s ograničenim očekivanjem trajanja života, a većina je bila s primarnom dijagnozom neizlječivog raka; ostale primarne dijagnoze uključivale su terminalni stadij KOPB/emfizema, kardiovaskularnu bolest/zatajenje srca, Alzheimerovu bolest/demenciju, HIV/AIDS ili druge uznapredovale bolesti.
The capped syringe or syringe and needle should NEVER be reused. 
Štrcaljka s pokrovom ili štrcaljka s iglom se NIKADA ne smiju ponovno upotrijebiti.
Methylnaltrexone bromide is a selective antagonist of opioid binding at the mu-receptor. 
Metilnaltreksonbromid je selektivni antagonist vezivanja opioida na mu-receptor.
Patient weight in kg Fill syringe to mL level (dose) Less than 38 kg 
Težina bolesnika u kg Štrcaljku napuniti do oznake ml (doza) Manje od 38 kg
Women using this medicine should not breast-feed, since it is not known if methylnaltrexone bromide passes into human breast milk. 
Žene koje uzimaju ovaj lijek ne smiju dojiti budući da nije poznato izlučuje li se metilnaltreksonbromid u majčino mlijeko.
Opioid-induced constipation in adult patients with advanced illness Methylnaltrexone bromide treatment has not been studied in adult patients with advanced illness in clinical trials for longer than 4 months, and should therefore only be used for a limited period (see section 5.1). 
Konstipacija uzrokovana opioidima u odraslih bolesnika s uznapredovalom bolešću Liječenje metilnaltreksonbromidom nije ispitivano u odraslih bolesnika s uznapredovalom bolešću u kliničkim ispitivanjima duže od 4 mjeseca te ga stoga treba primjenjivati samo u ograničenom razdoblju (vidjeti dio 5.1).
Pack sizes of 4, 7, 8 and 10 pre-filled syringes. 
Veličine pakiranja: 4, 7, 8, i 10 napunjenih štrcaljki.
Paediatric population No studies have been performed in the paediatric population (see section 4.2). 
Na pedijatrijskoj populaciji nisu provedena ispitivanja (vidjeti dio 4.2).
Following intravenous injection of methylnaltrexone bromide, juvenile rats were found to be more sensitive than adult rats to methylnaltrexone-related toxicity. 
Nakon primanja intravenske injekcije metilnaltreksonbromida, utvrđeno je da su mladi štakori osjetljiviji od odraslih štakora na toksičnost povezanu s metilnaltreksonbromidom.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with methylnaltrexone bromide should be made, taking into account the benefit of breast-feeding to the child and the benefit of methylnaltrexone bromide therapy to the woman. 
Potrebno je odlučiti da li nastaviti/prekinuti dojenje ili nastaviti/prekinuti liječenje metilnaltreksonbromidom uzimajući u obzir korist dojenja za dijete i korist liječenja metilnaltreksonbromidom za ženu.
- If you or your doctor know that your bowels were or are obstructed or your bowels are in a state where there is an immediate need for surgical intervention (which has to be diagnosed by your doctor). 
- Ako Vi ili Vaš liječnik znate da su Vaša crijeva bila ili su začepljena ili da su Vaša crijeva u stanju u kojem postoji hitna potreba za kirurškim zahvatom (takvo stanje mora dijagnosticirati
Severe renal impairment decreased the renal clearance of methylnaltrexone bromide by 8- to 9-fold; however, this resulted in only a 2-fold increase in total methylnaltrexone bromide exposure (AUC). 
Teško oštećenje bubrega dovelo je do smanjenja renalnog klirensa metilnaltreksonbromida za 8 do 9 puta; međutim, ovo je dovelo do samo dvostrukog povećanja ukupne izloženosti metilnaltreksonbromidu (AUC).
Patients with severe renal impairment whose weight falls outside the 62 to 114 kg range (see section 5.2) need to reduce their mg/kg dose by 50 %. 
Bolesnicima s teškim oštećenjem bubrega čija je težina izvan raspona od 62 do 114 kg (vidjeti dio 5.2), potrebno je smanjiti dozu u mg/kg za 50%.
If you experience any of these side effects, which are either severe or will not go away, you should talk to your doctor: 
Ukoliko doživite bilo koju od tih nuspojava koje su teške ili ne prolaze, morate se obratiti svom liječniku:
These patients should use Relistor vials and not the pre-filled syringe. 
Ovi bolesnici moraju koristiti bočice Relistora, a ne napunjenu štrcaljku.
Assemble the supplies you will need for your injection. 
Složite sve predmete koji su Vam potrebni za injekciju.
If you forget a dose, talk to your doctor or pharmacist as soon as possible. 
Ako zaboravite uzeti jednu dozu, što prije se obratite svojem liječniku ili ljekarniku.
Relistor is given as a subcutaneous injection. 
Relistor se daje kao supkutana injekcija.
If severe or persistent diarrhoea occurs during treatment, patients should be advised not to continue therapy with methylnaltrexone bromide and consult their physician. 
Pojavi li se tijekom liječenja težak ili trajan proljev, bolesnicima treba savjetovati da ne nastavljaju liječenje metilnaltreksonbromidom te da se posavjetuju sa svojim liječnikom.
Do not attempt to administer an injection until you are sure that you understand how to give the injection. 
Nemojte pokušavati dati injekciju dok niste sigurni da razumijete kako dati injekciju.
In palliative care patients, Relistor is added to usual laxative treatment (see section 5.1). 
U bolesnika koji primaju palijativnu skrb, Relistor se dodaje liječenju uobičajenim laksativima (vidjeti dio 5.1).
For patients with long-term pain (except patients receiving supportive care for advanced illness), fill the syringe to the 0.6 mL mark for 12 mg of Relistor. 
Za bolesnike s dugoročnom boli (osim bolesnika koji primaju suportivnu skrb za uznapredovalu bolest) napunite štrcaljku do oznake od 0,6 ml za 12 mg lijeka Relistor.